- 全部删除
您的购物车当前为空
Tebufelone 是一种体外高效的CO 抑制剂 ,是一种新型的非甾体抗炎药(NSAID),属于二叔丁基苯酚(DTBP)类,在各种动物模型中显示出强大的抗炎、镇痛和抗网膜炎特性。Tebufelone 能有效地抑制前列腺素(PGE2)的形成,阻止大鼠巨噬细胞(IC50 = 20 microM)和人类全血(IC50 = 22 microM)中脂氧酶途径的产物[白三烯(LTB4)]的体外形成。


为众多的药物研发团队赋能,
让新药发现更简单!
Tebufelone 是一种体外高效的CO 抑制剂 ,是一种新型的非甾体抗炎药(NSAID),属于二叔丁基苯酚(DTBP)类,在各种动物模型中显示出强大的抗炎、镇痛和抗网膜炎特性。Tebufelone 能有效地抑制前列腺素(PGE2)的形成,阻止大鼠巨噬细胞(IC50 = 20 microM)和人类全血(IC50 = 22 microM)中脂氧酶途径的产物[白三烯(LTB4)]的体外形成。
| 规格 | 价格 | 库存 | 数量 |
|---|---|---|---|
| 1 mg | ¥ 538 | In stock | |
| 5 mg | ¥ 1,290 | In stock | |
| 10 mg | ¥ 1,950 | In stock | |
| 25 mg | ¥ 3,290 | In stock | |
| 50 mg | ¥ 4,720 | In stock | |
| 100 mg | ¥ 6,590 | In stock | |
| 500 mg | ¥ 12,900 | In stock | |
| 1 mL x 10 mM (in DMSO) | ¥ 1,230 | In stock |
Tebufelone 相关产品
| 产品描述 | Tebufelone is a potent in vitro inhibitor of CO , a novel non-steroidal anti-inflammatory drug (NSAID) belonging to the di-tert-butylphenol (DTBP) class that has shown potent anti-inflammatory, analgesic and anti-reticulitis properties in various animal models. Tebufelone potently inhibits the formation of prostaglandins (PGE2) and blocks the formation of lipoxygenase pathway products [leukotriene (LTB4)] in rat macrophages (IC50 = 20 microM) and human whole blood (IC50 = 22 microM) in vitro. = 20 microM) and human whole blood (IC50 = 22 microM) from the formation of lipoxygenase pathway products [leukotriene (LTB4)] in vitro. |
| 体内活性 | Tebufelone(25、50、100或200 mg)服用后30分钟,静脉注射了E. coli内毒素(2ng/kg)。自给药后30分钟起,每15分钟记录一次口腔温度,直到内毒素给药后8小时。经过基线调整的体温曲线下面积(AUCs)显著低于安慰剂组,ASA和除25 mg Tebufelone组外的所有组别均是如此。[1] |
| 别名 | 特丁非隆 |
| 分子量 | 300.44 |
| 分子式 | C20H28O2 |
| CAS No. | 112018-00-5 |
| Smiles | OC1=C(C(C)(C)C)C=C(C(CCCC#C)=O)C=C1C(C)(C)C |
| 颜色 | White |
| 物理性状 | Solid |
| 存储 | Powder: -20°C for 3 years | In solvent: -80°C for 1 year | Shipping with blue ice/Shipping at ambient temperature. | ||||||||||||||||||||||||||||||
| 溶解度信息 | DMSO: 30 mg/mL (99.85 mM), Sonication is recommended. | ||||||||||||||||||||||||||||||
溶液配制表 | |||||||||||||||||||||||||||||||
DMSO
| |||||||||||||||||||||||||||||||
评论内容